Active ingredientVorolanibCat. No. P-V063-001CAS 1013920-15-4Family · Pharmaceutical analytical standards
Vorolanib
An oral tyrosine kinase inhibitor that blocks both VEGFR and PDGFR receptors, slowing the formation of new blood vessels in tumours; approved in China in 2023, together with everolimus, for advanced renal cell carcinoma. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Besides oncology it has been studied for neovascular age-related macular degeneration, an eye disease in which abnormal blood vessels grow in the retina and choroid.
Go to the active ingredient →Active ingredientVorolanibCat. No. P-V063-001CAS 1013920-15-4
Isotopically labelledVorolanib Impurity 1-13C-d3Cat. No. P-V063-002
Isotopically labelledVorolanib-d6Cat. No. P-V063-003
ImpurityVorolanib Impurity 1Cat. No. P-V063-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.